NCT02204033View on ClinicalTrials.gov

Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 1999

Primary Completion Date

June 30, 2001

Conditions
Head and Neck Neoplasms
Interventions
DRUG

99mTc - labelled hMAb BIWA 4

DRUG

186 Re - labelled hMAb BIWA 4

DRUG

unlabelled hMAb BIWA 4 - low dose

DRUG

unlabelled hMAb BIWA 4 - medium dose

DRUG

unlabelled hMAb BIWA 4 - high dose

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY